Compound: methocarbamol
SMILES: O=C(OCC(O)COc1c(OC)cccc1)N
InChIKey: GNXFOGHNGIVQEH-UHFFFAOYSA-N
Synonyms: methocarbamol, 532-03-6, Robaxin, Metocarbamol, Miolaxene, Relestrid, Surquetil, Tresortil, Delaxin, Etroflex, Miorilas, Avetil, Miowas, Metocarbamolo, Metofenina, Myolaxene, Reflexyn, Romethocarb, Robinax, 2-Hydroxy-3-(2-methoxyphenoxy)propyl carbamate, Forbaxin, Guaiphenesin carbamate, Guaiacol glyceryl ether carbamate, Guaiphenesine carbamate, Glycerylguaiacolate carbamate, AHR 85, Methocarbamolum, 1,2-Propanediol, 3-(2-methoxyphenoxy)-, 1-carbamate, Guiacol-gliceriletere monocarbammato, 3-(o-Methoxyphenoxy)-2-hydroxypropyl carbamate, ROBAXIN-750, 3-(2-Methoxyphenoxy)-1-glyceryl carbamate, DTXSID6023286, 2-Hydroxy-3-(o-methoxyphenoxy)propyl 1-carbamate, 3-(o-Methoxyphenoxy)-1,2-propanediol 1-carbamate, NSC-170960, 1,2-Propanediol, 3-(o-methoxyphenoxy)-, 1-carbamate, 125OD7737X, DTXCID503286, CHEBI:77498, NSC170960, Carbamate, Guaiphenesin, Miolaxin, Tanlor, Robaxin-V Tablets, Methocarbamol Tablets, METHCARBAMOL, Robaxin-V Injectable, Methocarb 500-EZS, RefChem:55604, CHEBI:6832, Methocarbamol Granules DC 90%, M03BA03, Methocarbamol Tablets, USP, 500 mg, Methocarbamol Tablets, USP, 750 mg, 208-524-3, 927-845-6, Lumirelax, Perilax, Neuraxin, Parabaxin, Methocal, Metofenia, Glycerylguajacol-carbamat, Robaxan, Robaxine, Robaxon, [2-hydroxy-3-(2-methoxyphenoxy)propyl] carbamate, MFCD00057662, NSC 170960, MLS000028610, Carbamic acid, 2-hydroxy-3-(o-methoxyphenoxy)propyl ester, 3-(2-Methoxyphenoxy)-1,2-propanediol 1-carbamate, s1736, Robamol, SMR000058719, Traumacut, Metocarbamolo [DCIT], Robaxisol, Metocarbamol [INN-Spanish], Methocarbamolum [INN-Latin], HSDB 3122, 2-hydroxy-3-(2-methoxyphenoxy)propyl aminooate, SR-01000000240, EINECS 208-524-3, BRN 1884446, UNII-125OD7737X, NCGC00016492-01, CAS-532-03-6, Methocarbamol [USP:INN:BAN:JAN], Prestwick_614, Delaxin (TN), Robaxin (TN), Robaxisol (Salt/Mix), Spectrum_000997, Methocarbamol (Robaxin), Methocarbamol (Standard), Opera_ID_1471, Prestwick0_000184, Prestwick1_000184, Prestwick2_000184, Prestwick3_000184, Spectrum2_001272, Spectrum3_000496, Spectrum4_000049, Spectrum5_000956, GlyTouCan:G76284QI, METHOCARBAMOL [MI], 2-Hydroxy-3-(o-methoxyphenoxy)propyl carbamate, METHOCARBAMOL [INN], METHOCARBAMOL [JAN], METHOCARBAMOL [HSDB], SCHEMBL34365, BSPBio_000107, BSPBio_001991, KBioGR_000517, KBioSS_001477, METHOCARBAMOL [VANDF], MLS001148605, DivK1c_000434, METHOCARBAMOL [MART.], SPECTRUM1500397, WLN: ZVO1YQ1OR BO1, SPBio_001264, SPBio_002028, METHOCARBAMOL [USP-RS], METHOCARBAMOL [WHO-DD], BPBio1_000119, GTPL6829, Methocarbamol (JAN/USP/INN), orb1308699, (+-)-3-(o-Methoxyphenoxy)-1,2-propanediol 1-carbamate, CHEMBL1201117, SCHEMBL29360915, HMS501F16, HY-B0262R, KBio1_000434, KBio2_001477, KBio2_004045, KBio2_006613, KBio3_001491, Carbamic Acid 2-Hydroxy-3-(2-methoxyphenoxy)propyl Ester, NINDS_000434, GLXC-23106, HMS1568F09, HMS1920L19, HMS2091D14, HMS2095F09, HMS2233G18, HMS3259M17, HMS3369B17, HMS3655O06, HMS3712F09, HMS5079H20, METHOCARBAMOL [GREEN BOOK], Pharmakon1600-01500397, METHOCARBAMOL [ORANGE BOOK], 145841-69-6, G76284QI, HY-B0262, Tox21_110454, CCG-39655, EBC-03743, METHOCARBAMOL [USP MONOGRAPH], NSC757112, SBB056990, AKOS015960743, Tox21_110454_1, DB00423, FM25163, NC00509, NSC-757112, IDI1_000434, ROBAXISAL COMPONENT METHOCARBAMOL, NCGC00018257-02, NCGC00018257-03, NCGC00018257-04, NCGC00018257-07, NCGC00018257-08, NCGC00018257-16, NCGC00089805-02, NCGC00089805-03, 1, 3-(o-methoxyphenoxy)-, 1-carbamate, AC-12037, AS-11691, DA-65368, SY035642, 1, 3-(2-methoxyphenoxy)-, 1-carbamate, SBI-0051442.P003, 3-O-(2-Methoxyphenyl)-1-glyceryl carbamate, AB00052040, M2254, NS00001031, ST50993887, SW196781-3, D00402, D70323, EN300-119525, AB00052040-15, AB00052040_16, AB00052040_17, 2-Hydroxy-3-(2-methoxyphenoxy)propyl carbamate #, F541672, Q411456, SR-01000000240-2, SR-01000000240-3, (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate, BRD-A31521121-001-05-8, BRD-A31521121-001-25-6, BRD-A31521121-001-26-4, Guaiacol glyceryl ether carbamate, analytical standard, 2-hydroxy-3-{[2-(methyloxy)phenyl]oxy}propyl carbamate, Z1521553984, carbamic acid [2-hydroxy-3-(2-methoxy-phenoxy)-propyl] ester, (+/-)-3-(O-METHOXYPHENOXY)-1,2-PROPANEDIOL 1-CARBAMATE, Methocarbamol, United States Pharmacopeia (USP) Reference Standard, 1,2-PROPANEDIOL, 3-(2-METHOXYPHENOXY)-, 1-CARBAMATE, (+/-)-, Methocarbamol, Pharmaceutical Secondary Standard; Certified Reference Material, 3967-43-9
Theoretical properties:
molecular_formula: C11H15NO5
molecular_weight: 241.24 g/mol
exact_mass: 241.09502258 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 7
heavy_atom_count: 17
topological_polar_surface_area: 91 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Crystals from benzene
color: Crystals from benzene
solubility: 2.5g/100mL
Descriptions:
{"pubchem": "2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate is a carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester. It is a carbamate ester, an aromatic ether and a secondary alcohol.", "chebi": "A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.", "chembl": "METHOCARBAMOL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain. It may be used together with rest, physical therapy, and pain medication. It has limited use for rheumatoid arthritis and cerebral palsy. Effects generally begin within half an hour. It is taken by mouth or injection into a vein.\nCommon side effects include headaches, sleepiness, and dizziness. Serious side effects may include anaphylaxis, liver problems, confusion, and seizures. Use is not recommended in pregnancy and breastfeeding. Because of the risk of injury, skeletal muscle relaxants should generally be avoided in geriatric patients. Methocarbamol is a centrally acting muscle relaxant. How it works is unclear, but it does not appear to affect muscles directly.\nMethocarbamol was developed in 1956 in the laboratories of A. H. Robins (later acquired by Pfizer). Studies were directed towards the development of propanediol derivatives which possessed muscle relaxant properties superior to those of mephenesin, which had low potency and a short duration of action. It was approved for medical use in the United States in 1957. It is available as a generic medication. In 2023, it was the 121st most commonly prescribed medication in the United States, with more than 5 million prescriptions. Methocarbamol is available in a fixed-dose combination with ibuprofen as methocarbamol/ibuprofen (sold under the brand name Summit Ultra)."}